Moreover, our findings suggest that supplementation with exogenous BMP9 or BMP10 might be a therapeutic strategy in decompensated cirrhosis and in PoPH and HPS, conditions with a major unmet need. This evidence concerns the gene GDF2 and Pulmonary arterial hypertension associated with portal hypertension.